抗CD47靶向治疗研究现状及应用前景

发布时间：2018-05-19 18:04

本文选题：CD + 单克隆抗体　；参考：《中国肿瘤临床》2017年07期

【摘要】：在肿瘤发生发展过程中,肿瘤细胞逃逸了免疫系统的监视;免疫逃逸机制对于研发新的抗肿瘤治疗方案具有重要的意义。免疫治疗旨在激活患者自身的免疫系统,是肿瘤治疗相关研究的前沿,具有广阔的应用前景。CD47是一种广泛表达的细胞表面分子,肿瘤细胞可能借此"别吃我"信号,逃避了肿瘤免疫;肿瘤干细胞中CD47的表达水平甚至比肿瘤细胞更高。通过使用抗CD47抗体阻断CD47-SIRPα通路,从而介导细胞吞噬作用,能够靶向性杀伤肿瘤细胞。现在多项关于CD47靶向治疗的临床试验正在进行中,包括两种单克隆抗体和一种融合蛋白。然而由于使用动物模型不一,可能高估了这些药物的临床疗效预测。现将CD47抗肿瘤治疗相关研究的背景及潜在问题加以综述,并对该治疗的未来应用前景予以展望。
[Abstract]:In the process of tumorigenesis and development, tumor cells escape from the monitoring of the immune system, and the mechanism of immune escape is of great significance for the development of new anti-tumor treatment schemes. Immunotherapy aims to activate the patient's own immune system, and is the frontier of tumor therapeutic-related research. CD47 is a widely expressed cell surface molecule, which may be used by tumor cells to signal "Don't eat me." It evades tumor immunity; CD47 expression in tumor stem cells is even higher than in tumor cells. By blocking the CD47-SIRP 伪 pathway by using anti CD47 antibodies, phagocytosis can be mediated and targeted to kill tumor cells. A number of clinical trials are underway on CD47 targeting therapy, including two monoclonal antibodies and a fusion protein. However, the use of animal models may overestimate the clinical efficacy of these drugs. In this paper, the background and potential problems of CD47 antitumor therapy are reviewed, and the prospect of its application in the future is prospected.
【作者单位】：天津医科大学肿瘤医院超声诊疗科国家肿瘤临床医学研究中心天津市肿瘤防治重点实验室天津市恶性肿瘤临床医学研究中心;哥伦比亚特区大学;
【基金】：国家自然科学青年基金资助项目(编号:81502247)资助~~
【分类号】：R730.51

【参考文献】